Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Calcifediol Patent Expiration

Calcifediol is Used for treating secondary hyperparathyroidism in patients with chronic kidney disease. It was first introduced by Organon Usa Inc in its drug Calderol on Approved Prior to Jan 1, 1982. Another drug containing Calcifediol is Rayaldee. 2 different companies have introduced drugs containing Calcifediol.


Calcifediol Patents

Given below is the list of patents protecting Calcifediol, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Rayaldee US10213442 Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 Feb 02, 2027 Eirgen
Rayaldee US10300078 Stabilized modified release vitamin D formulation and method of administering same Mar 14, 2034 Eirgen
Rayaldee US10357502 Stabilized modified release vitamin D formulation and method of administering same Mar 14, 2034 Eirgen
Rayaldee US11154509 Methods for controlled release oral dosage of a vitamin D compound Apr 25, 2028 Eirgen
Rayaldee US11253528 Stabilized modified release Vitamin D formulation and method of administering same Mar 14, 2034 Eirgen
Rayaldee US11801253 Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease Sep 07, 2030 Eirgen
Rayaldee US6582727 Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same Aug 22, 2020

(Expired)

 Eirgen
Rayaldee US8207149 Method for treating secondary hyperparathyroidism in CKD Apr 25, 2028 Eirgen
Rayaldee US8361488 Methods and compositions for controlled release oral dosage of a vitamin D compound Jul 19, 2028 Eirgen
Rayaldee US8426391 Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 Aug 27, 2028 Eirgen
Rayaldee US8778373 Methods for controlled release oral dosage of a vitamin D compound Apr 25, 2028 Eirgen
Rayaldee US8906410 Oral dosage form of 25-hydroxyvitamin D Feb 02, 2027 Eirgen
Rayaldee US9408858 Method for treating secondary hyperparathyroidism in CKD Apr 25, 2028 Eirgen
Rayaldee US9498486 Method for controlled release oral dosage of a vitamin D compound Apr 25, 2028 Eirgen
Rayaldee US9861644 Stabilized modified release vitamin D formulation and method of administering same Mar 14, 2034 Eirgen
Rayaldee US9925147 Method for treating secondary hyperparathyroidism in CKD Apr 25, 2028 Eirgen
Rayaldee US9943530 Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 Feb 02, 2027 Eirgen


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Calcifediol's patents.

Given below is the list recent legal activities going on the following patents of Calcifediol.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 22 May, 2024 US9498486
Payment of Maintenance Fee, 8th Year, Large Entity 09 Feb, 2024 US9408858
Payment of Maintenance Fee, 12th Year, Large Entity 26 Dec, 2023 US8207149
Recordation of Patent eGrant 31 Oct, 2023 US11801253
Patent Issue Date Used in PTA Calculation 31 Oct, 2023 US11801253
Mail Patent eGrant Notification 31 Oct, 2023 US11801253
Recordation of Patent Grant Mailed 31 Oct, 2023 US11801253
Email Notification 31 Oct, 2023 US11801253
Patent eGrant Notification 31 Oct, 2023 US11801253
Email Notification 12 Oct, 2023 US11801253



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳